Anti-CD20 monoclonal antibody and the BTK inhibitor
2026-50
Phase 1 small_molecule active
Quick answer
Anti-CD20 monoclonal antibody and the BTK inhibitor for Anti-CD20 Monoclonal Antibody is a Phase 1 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Anti-CD20 Monoclonal Antibody
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active